Audit a URL →

Sign in Sign up free

Loading…

Weekly · Sunday Morning

Five longevity claims.
Worth your time.
Every Sunday.

Last Sunday

Rapamycin extends mouse lifespan 9–14%
NAD+ precursors reverse aging in humans
Blue-light glasses improve sleep quality
Walking 10 min after meals blunts glucose
Verdict change — caffeine half-life downgraded

5 audits·1 verdict change·0 affiliate links·Every Sunday

Joining 1,247 readers — founders, MDs, and longevity-obsessed people who fact-check their own health decisions.

Browse

Decisions Claims Content Creators

Product

Audit a URL Sunday roundup API (soon)Pricing

About

FAQ Methodology Editorial Standards Corrections Press & brand RSS feed

Legal

Terms of Service Privacy Policy DMCA

Finally, something serious in this space.
Because we actually read the papers.

© 2026 Whalespan. Independent, evidence-graded longevity.

How does metformin compare to other geroprotective drugs? — Whalespan

Content›Video›How does metformin compare t…

How does metformin compare to other geroprotective drugs?

Peter Attia9m · 2024-05-15

Claims Made

10

Claims Supported

4

Support Rate

40%

Support rate

4 of 10 claims supported

4 supported6 partial / not

Claims from this content

6

◐Partially SupportedThe TAME trial for metformin is in a preliminary state, with enrollment currently starting after securing initial funding.✓Well SupportedA 2014 paper by Banister et al. analyzed a UK registry of type 2 diabetes patients on metformin versus matched controls to study geroprotection.✕Not SupportedMetformin failed in the ITP for geroprotective potential.✕Not SupportedMetformin alone did not succeed in the Interventions Testing Program (ITP) studies.◐Partially Supported

More from Peter Attia

Peter Attia on Zone 2 Cardio

Peter Attia on Rapamycin (with Matt Kaeberlein)

Attia walks back the clinic protocol: too aggressive for healthy adults

Discussion

Native comments, Twitter mentions, and Reddit threads about this content — surfaced together so the conversation isn't fragmented across platforms.

M

Share your read of this content…

Posting publicly as you · linked to your social profiles

Sort by:

AV

A. Volkovreader

4h

Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.

NP

N. Park

2d

Would love a "what would change this verdict" RSS feed. Sign me up if it exists.

The Keys et al. (2022) study results are consistent with increased mortality risk in diabetics on metformin, even when accounting for informative censoring.

✕Not SupportedThe Banister study had methodological flaws including informative censoring of sicker patients.